Cardiology

Ambulatory BP Monitoring – MM1310

Hypertension is a major risk factor for cardiovascular (CV) morbidity and mortality.1 Therefore, accurate measurement of blood pressure (BP) is essential to timeously identify individuals at risk and to monitor the efficacy of interventions and treatment adjustments. However, traditional office or clinic BP measurement provides only limited information and may be difficult to interpret, being based on a single or small set of readings dependent on the
technical skills of the clinician.

Modern Medicine – October 2013

Unexplained Syncope: 30 Months to Diagnosis Patient Case Study – MM1309

This patient presented to a hospital emergency department following an episode of syncope in June 2009. He was at home, talking on the telephone, when the event occurred. He experienced no lightheadedness or incontinence and described the event as “like how you feel after an amusement park ride”.
Patient was admitted and hospitalised for two days.

Modern Medicine – September 2013

Recent Advances in the Treatment of Atrial Fibrillation – MM1304

Atrial fibrillation occurs in paroxysmal, persistent or permanent forms. New anti-arrhythmic agents are being trialed for the pharmacological treatment of affected patients, and catheter ablation is an effective therapeutic intervention for the treatment of patients with symptomatic, drug-refractory paroxysmal atrial fibrillation.

Modern Medicine – April 2013

Patients Post Myocardial Infarction -Tailored Management Improves Outcomes – MM1303

Patients who have had a myocardial infarction need aspirin and statin therapy and careful evaluation to identify those who will benefit from revascularisation  or implantable device therapy and appropriate additional pharmacological treatment.

Modern Medicine – March 2013

Update on Lipid Management – Commonly Asked Questions – MM1302

Target levels for LDL-cholesterol (LDL-C) in patients with cardiovascular
disease (CVD) are being lowered. New statin combinations will
be more cost effective than present combinations and will help to
achieve LDL-C targets. These and other drugs in development promise
a new era in CVD prevention.

Modern Medicine – February 2013